1. Introduction {#sec0005}
===============

Pancreatic neuroendocrine tumors (pNET) are rare, presenting with synchronous metastases in up to 65% of patients. There are few reports of patients with metachronous metastases from NETs although prolonged survival is well-known [@bib0005]. Aggressive local management (surgery, radio-frequency ablation \[RFA\], etc.) is advocated for both the primary tumor and metastases [@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025]. Most metastatic lesions from pNETs are in the liver. In a series of NETs from a national registry in Spain, including 837 patients, synchronous metastases were found in 44% of patients, including in the liver (42%), lymph nodes, peritoneal surface, bone, lung, central nervous system and adrenal gland. All four patients with synchronous adrenal tumors had metastatic disease in other sites [@bib0030].

The present patient has been previously reported as the first patient with a metastasis to the spleen from a primary pNET, approximately 90 months prior to this presentation [@bib0005]. The patient has been followed closely at a major university hospital with imaging at regular intervals, and has remained asymptomatic, but presents now with a right adrenal gland mass. This is the first report of an isolated metachronous metastasis from a pNET to the adrenal gland.

2. Case presentation {#sec0010}
====================

The patient initially presented as a 53y old white male with anemia and fatigue. Past medical history, social history and family history are unremarkable. Physical exam showed a left upper quadrant fullness and was otherwise negative. Computed tomography (CT) scan of the abdomen showed a 24 cm left upper quadrant mass with multiple liver lesions, splenomegaly and a 1 cm mass in the spleen. Treatment over the next 78 months is described in detail elsewhere. ([Fig. 1](#fig0005){ref-type="fig"}) [@bib0005]. Briefly, he underwent gastrectomy, splenectomy, distal pancreatectomy and resection of small bowel and colon. The spleen contained a 1.0 cm metastatic lesion [@bib0005]. The final pathology showed a pNET, well differentiated, stage T4N0M1 with 0/13 lymph nodes containing tumor and an isolated metastasis to the spleen. There were three mitoses per 50 high power fields, and Ki-67 \< 1%. Immunostains for chromogranin A and synaptophysin are positive. Immunostains for CD56, OCGH1E5, AFP, glucagon, insulin, somatostatin, pancreatic polypeptide, alpha 1-anti trypsin, alpha 1 anti-chymotrypsin and lipase were negative. Blood chemistry studies showed that this was a non-functional tumor.Fig. 1Treatment history and serum PIVKA levels for 90months prior to the current presentation. Each intervention is marked by a serum PIVKA level before and after. Serum PIVKA levels are elevated for five of seven recurrences, and then return to normal after treatment. Serum PIVKA was not elevated before two of the radiofrequency ablation (RFA) procedures.Fig. 1

Over the next 90 months, the patient underwent a left lateral segmentectomy of the liver to resect synchronous metastatic disease (82 months previously), RFA of a central hepatic lesion (68 months previously), resection of multiple hepatic nodules (53 months previously), RFA of another liver mass (33 months previously), and RFA of a liver mass (14 months previously). CT scans have been obtained at three-month intervals and serum PIVKA levels checked monthly ([Fig. 1](#fig0005){ref-type="fig"}). The patient receives somatostatin, long acting release, 20 mg/month. All recurrences were initially identified on imaging studies. Lesions (three) treated with RFA had no pathologic confirmation, but resected liver lesions (two) were histologically confirmed as metastases.

At 90months after resection of the primary tumor, routine CT scan showed a mass in the right adrenal gland ([Fig. 2](#fig0010){ref-type="fig"}). The patient is asymptomatic, and physical examination is unremarkable. Laboratory studies show no elevated serum hormone levels. Serum PIVKA level was 44 Arbitrary Units (AU)/ml (Reference \<40 AU/ml). Magnetic resonance imaging showed a 3 cm lesion in the right adrenal gland, enhanced on T2 weighted images ([Fig. 3](#fig0015){ref-type="fig"}). There are no other lesions in the abdomen, including the liver. The patient underwent a laparoscopic right adrenalectomy (with hand-assist because of dense adhesions to the liver). There were no postoperative complications.Fig. 2Computed tomography scans of the abdomen show a 2.5 cm mass in the right adrenal gland (arrow). Left upper image: non-enhanced, left lower: early arterial phase, right upper: late arterial phase, right lower: late portal phase. The tumor is markedly enhanced in the early arterial phase but not in the portal phase.Fig. 2Fig. 3Magnetic resonance imaging shows an enhanced 3 cm mass in the right adrenal gland (arrow). Left upper image: T1-weighted image, left lower: T2-weighted image, right upper: dynamic sequence, right lower: Diffusion weighted image (DWI) sequence (b = 1000). The adrenal gland tumor is markedly enhanced in the early arterial phase (similar to the computed tomography images). The T2-weighted image shows a high intensity signal and diffusion restriction is noted in the DWI sequences.Fig. 3

In summary, the patient is a 60yo man who presented 90 months previously with a pNET Stage IV, T4N0M1, Ki-67 index \<1%, CD56 −, synaptophysin+ and chromogranin A+, with synchronous metastases to the spleen and liver. In addition to resection of the primary lesion and synchronous spleen metastasis, he has undergone two open liver resections, and three episodes of percutaneous RFA for liver metastases. He presented with a metachronous metastatic lesion in the right adrenal gland ([Fig. 4](#fig0020){ref-type="fig"}), which was resected, measuring 3 × 2 × 2 cm, with a Ki-67 index of 15--20%, and is CD56+, synaptophysin+ and chromogranin A+.Fig. 4Histology of the right adrenal mass. Left Upper: Macroscopic image shows a 3 cm tumor in the right adrenal gland. Right Upper: Microscopic findings (Hematoxylin and eosin stain, ×100) shows the border of the adrenal gland tissue with a nest of neuroendocrine cells. Left Lower: The tumor cells were weakly positive for chromogranin A by immunohistochemical staining (×100) while strongly positive for synaptophysin (Right Lower, ×100).Fig. 4

3. Discussion {#sec0015}
=============

This is the first report of a metachronous metastasis from a pNET to the adrenal gland, 90 months after initial presentation. There are previous reports of five patients with synchronous metastases to the adrenal gland [@bib0030], [@bib0035]. Of these, details are available for one patient, and the adrenal lesion was found with widely disseminated disease [@bib0035]. The other four patients were reported as aggregate data in patients with synchronous metastases [@bib0030], and were also seen with disseminated disease. In a review of a single-center experience over 30 years with 464 patients with adrenal gland metastases, the mean latent period was seven months [@bib0040]. Lung was the most common primary tumor (35%) with other sites including stomach (14%), esophagus (12%) and liver/bile ducts (10%. There were no NET primary tumors in this large series.

In a study of rare sites of metastases from NETs, investigators found lesions in the heart, breast, retro-orbital, uterus, skin, brain, spleen, testes, seminal vesicle and peripheral muscle [@bib0045]. There were no lesions of the adrenal gland in this series. Several reports have described the treatment of metastases to the adrenal gland, from primary tumors such as the lung [@bib0050], colon [@bib0055] and kidney [@bib0060], [@bib0065]. In an early review of the treatment of isolated metastases to the adrenal gland, resection was recommended in patients with a disease-free interval of greater than 6 months [@bib0070]. This collective review reviewed 37 patients with primary tumors of the lung, kidney and colon. The overall 5-year survival of the group was 24%, with a median survival of 21 months. In a retrospective review of 41 patients who underwent open or laparoscopic adrenalectomy for isolated metastatic disease, investigators concluded that laparoscopic adrenalectomy should be offered to patients with a disease-free interval of more than 6 months [@bib0075].

It is of interest in this patient that while the primary tumor had a Ki-67 index of \<1%, the adrenal metastasis has a Ki-67 index of 15--20%. Ki-67 is a cell surface antigen expressed in proliferating cells. It has been shown that tumor size and increased Ki-67 index are independent factors which correlate with a poor prognosis [@bib0080]. Ki-67 level was recently added to the standard grading system of NETs. Other important tumor markers in NETs include CD56, synaptophysin, and chromogranin A. While the primary tumor in this patient was CD56-, the metastasis to the adrenal gland is CD56+, which is typical in NETs. The role of these three cellular markers in the diagnosis of NETs has been investigated and a new marker, INSM1 has been identified for NET of the chest [@bib0085]. The role of this new marker in gastrointestinal tract NETs is undefined.

Serum PIVKA levels have been described for the diagnosis and follow-up of patients with hepatocellular carcinoma (HCC). They have also been used in conjunction with chromogranin A as markers for HCC [@bib0090]. The value of PIVKA as an early diagnostic marker was established in 2002 [@bib0090]. In one study, investigators found that PIVKA has a sensitivity of 75% in the initial diagnosis of HCC, and 74% for the diagnosis of recurrent disease [@bib0095]. However, there have been no reports of elevated PIVKA levels in patients with NET. The present patient underwent seven procedures to treat the primary lesion and six recurrences ([Fig. 1](#fig0005){ref-type="fig"}). Serum PIVKA levels were elevated before treatment of five of these lesions (primary + spleen, liver resection, liver resection, liver RFA and adrenal gland) and were not elevated before two sessions of RFA. It is impossible to calculate the sensitivity since there were no specimens obtained after all three RFA treatments. This observation suggests that serum PIVKA levels should be further investigated as a potentially useful tumor marker in patients with pNETs.

The development of another recurrent lesion in this patient who receives monthly injections of long acting somatostatin brings into question the value of continued therapy. This is a difficult question, for which there is little data to evaluate. However, since a number of studies have concluded that somatostatin is a worthwhile adjunct, it will be continued in this patient [@bib0005], [@bib0010], [@bib0025]. This patient has been asymptomatic through the development of multiple sites of recurrent disease which have been diagnosed by routine CT scans. Octreotide scans have only recently become available in Japan and may be a useful follow-up modality. Follow-up for this patient will include serum PIVKA levels and CT scans.

4. Conclusions {#sec0020}
==============

This patient presented 90 months previously with a Stage IV (T4N0M1) pNET. He has undergone four open resections and three sessions of percutaneous RFA to treat the primary tumor (with a synchronous spleen metastasis) and six recurrences (five in the liver and one in the adrenal gland). Features unique to this patient illustrate major teaching points including the first reported metastases from a pNET to the spleen [@bib0005] and adrenal gland, and elevated serum PIVKA levels as a potential tumor marker. This patient has undergone aggressive local treatment as well as monthly administration of somatostatin [@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025]. The appearance of an adrenal mass underscores the need for close follow-up.
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